However, we suggest that IRF8 may be unique in its lymphomagenic potential because it has also been associated with a variety of oncogenic structural defects [translocation, amplification, and super-enhancer deregulation (15–17)] in which excess of IRF8 expression may contribute to lymphoma development and progression. The gene discussed is IRF8; the disease is lymphoma.